Soligenix, Inc. (SNGX) announced a publication describing the preclinical efficacy of CiVax, a thermostabilized subunit vaccine against SARS-CoV-2. In collaboration with Axel Lehrer, Professor at the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine, University of Hawai?i at Manoa, the manuscript has been published in COVID.
Using custom-developed immunoassays, the combination of a primary adenovirus vaccine coupled with a CiVax booster was shown to induce broader protection against COVID-19 variants in non-human primates than a 2-shot mRNA series in humans.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.